Volume 359, Issue 9323, Pages (June 2002)

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Volume 9, Issue 2, Pages (February 2008)

Volume 13, Issue 2, Pages (February 2012)

Volume 379, Issue 9824, Pages (April 2012)

Volume 357, Issue 9273, Pages (June 2001)

Volume 370, Issue 9594, Pages (October 2007)

Volume 356, Issue 9239, Pages (October 2000)

Volume 357, Issue 9257, Pages (March 2001)

Pharmacogenetics and future drug development and delivery

Volume 12, Issue 11, Pages (October 2011)

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin.

Volume 376, Issue 9747, Pages (October 2010)

Volume 11, Issue 4, Pages (April 2012)

Volume 378, Issue 9785, Pages (July 2011)

Meta-analysis of randomised controlled trials

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

How to Treat MDS without Stem Cell Transplantation

Volume 371, Issue 9611, Pages (February 2008)

Volume 366, Issue 9482, Pages (July 2005)

Volume 14, Issue 3, Pages (March 2013)

Volume 15, Issue 8, Pages (July 2014)

Volume 366, Issue 9486, Pages (August 2005)

Volume 15, Issue 8, Pages (July 2014)

Volume 14, Issue 4, Pages (April 2015)

Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study Matthew Waxman, MD,

Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission Quoc Truong,

Volume 376, Issue 9757, Pages (December 2010)

Aspirin in the prevention of cancer – Author's reply

Volume 14, Issue 10, Pages (September 2013)

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin.

Volume 9, Issue 9, Pages (September 2008)

Volume 366, Issue 9482, Pages (July 2005)

Volume 373, Issue 9663, Pages (February 2009)

Volume 2, Issue 12, Pages (December 2015)

Volume 372, Issue 9642, Pages (September 2008)

Volume 2, Issue 6, Pages (June 2015)

Volume 9, Issue 10, Pages (October 2008)

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

Meta-analysis of randomised controlled trials

Volume 375, Issue 9732, Pages (June 2010)

Volume 356, Issue 9241, Pages (November 2000)

Volume 378, Issue 9785, Pages (July 2011)

Cold water immersion: sudden death and prolonged survival

Volume 63, Issue 3, Pages (March 2003)

Volume 9, Issue 9, Pages (September 2008)

Volume 20, Issue 1, Pages (January 2019)

Volume 14, Issue 11, Pages (October 2013)

Volume 12, Issue 8, Pages (August 2013)

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Volume 385, Issue 9962, Pages (January 2015)

Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 371, Issue 9627, Pages (May 2008)

Volume 376, Issue 9757, Pages (December 2010)

Volume 9, Issue 4, Pages (April 2008)

Volume 381, Issue 9880, Pages (May 2013)

Volume 13, Issue 9, Pages (September 2012)

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.

Volume 11, Issue 1, Pages (January 2010)

Volume 376, Issue 9757, Pages (December 2010)

Volume 371, Issue 9618, Pages (March 2008)

Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant Ahmad Hatem Mattour,

Volume 376, Issue 9747, Pages (October 2010)

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label.

Stem cell transplantation

Volume 1, Issue 1, Pages (June 2014)

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Volume 371, Issue 9611, Pages (February 2008)

Presentation transcript:

Volume 359, Issue 9323, Pages 2065-2071 (June 2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial Prof Norbert Schmitz, MD, Beate Pfistner, PhD, Michael Sextro, MD, Markus Sieber, MD, Prof Angelo M Carella, MD, Matthias Haenel, MD, Friederike Boissevain, MD, Prof Reinhart Zschaber, MD, Peter Müller, MD, Hartmut Kirchner, MD, Andreas Lohri, MD, Susanne Decker, MD, Bettina Koch, Dirk Hasenclever, PhD, Anthony H Goldstone, FRCPath, Prof Volker Diehl, MD The Lancet Volume 359, Issue 9323, Pages 2065-2071 (June 2002) DOI: 10.1016/S0140-6736(02)08938-9 Copyright © 2002 Elsevier Ltd Terms and Conditions

Figure 1 Study protocol Dexa-BEAM=dexamethasone and carmustine, etoposide, cytarabine, and melphalan; CR=complete remission; PR=partial remission; HSC=autologous haemopoietic stem cells; BM=bone marrow; HSCT=haemopoietic stem-cell transplantation. The Lancet 2002 359, 2065-2071DOI: (10.1016/S0140-6736(02)08938-9) Copyright © 2002 Elsevier Ltd Terms and Conditions

Figure 2 Trial profile CR=complete remission; PR=partial remission. The Lancet 2002 359, 2065-2071DOI: (10.1016/S0140-6736(02)08938-9) Copyright © 2002 Elsevier Ltd Terms and Conditions

Figure 3 Freedom from treatment failure for patients with relapsed chemosensitive Hodgkin's disease The Lancet 2002 359, 2065-2071DOI: (10.1016/S0140-6736(02)08938-9) Copyright © 2002 Elsevier Ltd Terms and Conditions

Figure 4 Freedom from treatment failure for patients with early relapse (upper), late relapse (middle), and multiple relapses (lower) of Hodgkin's disease The Lancet 2002 359, 2065-2071DOI: (10.1016/S0140-6736(02)08938-9) Copyright © 2002 Elsevier Ltd Terms and Conditions

Figure 5 Overall survival for patients with early relapse (upper), late relapse (middle), and multiple relapses (lower) of Hodgkin's disease. The Lancet 2002 359, 2065-2071DOI: (10.1016/S0140-6736(02)08938-9) Copyright © 2002 Elsevier Ltd Terms and Conditions